About CaDAnCe
The CaDAnCe study offers an investigational treatment for people like you with B-Cell Malignancies—specifically:
- Follicular Lymphoma
- Marginal Zone Lymphoma
- Mantle Cell Lymphoma
- Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma
- Waldenström Macroglobulinemia
- Diffuse Large B-Cell Lymphoma
- Richter's Transformation to Diffuse Large B-Cell Lymphoma
Depending on your type of malignancy, you may be eligible for this study if you'd had two or more previous treatments.
An Unmet Need
There are treatments for B-cell malignancies; however, B-cell malignancies can be or become resistant to existing treatments. Therefore, there remains a need for additional treatments to be developed. The main goal of the CaDAnCe study is to make sure that the treatment is safe for human use. Also, we want to find out the right amount of dosage that should be given in future studies by looking at how well this investigational treatment works initially for patients with B-cell malignancies.
About the Investigational Treatments
The investigational drug in this study — BGB-16673 — is:
Designed to be taken by
mouth daily.
Provided to all participants
in this study.
Benefits of Participation
If you choose to participate in the CaDAnCe clinical study, some of the benefits you will receive include:
Access to the investigational drug.
Close care and monitoring from experts in B-cell malignancies.
Potential reimbursement for travel and other expenses.
Patients who remain on the investigational drug through the end of the study, and who are continuing to benefit from taking it, may continue to receive the investigational drug after they finish their study participation.